Dampak Program Skrining Kanker terhadap Mortalitas

Oleh :

dr. Sunita

Program skrining kanker seperti kanker payudara, kanker paru, kanker kolorektal, dan kanker prostat selama ini dianggap dapat menurunkan mortalitas, tetapi hasil berbagai studi sebenarnya masih memperdebatkan hal ini. Program skrining kanker umumnya dapat mengurangi mortalitas spesifik yang terkait kanker yang diskrining, tetapi tidak mengurangi mortalitas umum secara bermakna.[1]

Penurunan mortalitas umum (overall mortality) yang tidak bermakna bila dibandingkan dengan penurunan mortalitas spesifik tersebut diduga terjadi karena studi-studi yang ada selama ini masih bersifat underpowered atau berjumlah sampel kurang banyak untuk menilai mortalitas umum. Selain itu, manfaat dari penurunan mortalitas spesifik biasanya “dikurangi” oleh kerugian jangka panjang dari skrining, yaitu overdiagnosis dan overtreatment karena hasil positif palsu.[1]

Jenis Mortalitas dalam Studi tentang Program Skrining Kanker

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Prasad V, Lenzer J, Newman DH. Why Cancer Screening Has Never Been Shown To “Save Lives”-And What We Can Do About It. BMJ. 2016;352(January):4–7.
2. Stang A, Jöckel K-H. The Impact Of Cancer Screening On All-Cause Mortality. Dtsch Arztebl Int [Internet]. 2018;115(29–30):481–6. https://www.aerzteblatt.de/10.3238/arztebl.2018.0481
3. Heijnsdijk EAM, Csanádi M, Gini A, et al. All-Cause Mortality Versus Cancer-Specific Mortality As Outcome In Cancer Screening Trials: A Review And Modeling Study. Cancer Med. 2019;8(13):6127–38.
4. Schröder FH, Hugosson J, Roobol MJ, et al. Screening And Prostate Cancer Mortality: Results Of The European Randomised Study Of Screening For Prostate Cancer (ERSPC) At 13 Years Of Follow-Up. Lancet. 2014;384(9959):2027–35. https://linkinghub.elsevier.com/retrieve/pii/S0140673614605250
5. Jodal HC, Helsingen LM, Anderson JC, et al. Colorectal Cancer Screening With Faecal Testing, Sigmoidoscopy Or Colonoscopy: A Systematic Review And Network Meta-Analysis. BMJ Open. 2019;9(10).
6. Bretthauer M, Løberg M, Wieszczy P, et al. Effect Of Colonoscopy Screening On Risks Of Colorectal Cancer And Related Death. N Engl J Med. 2022;387(17):1547–56. http://www.nejm.org/doi/10.1056/NEJMoa2208375
7. Carter SM. Why Does Cancer Screening Persist Despite The Potential To Harm? Sci Technol Soc. 2021;26(1):24–40. http://journals.sagepub.com/doi/10.1177/0971721820960252
8. Robra B-P. Ethical Challenges In Cancer Diagnosis And Therapy. 2021;85–104. https://doi.org/10.1007/978-3-030-63749-1_7
9. Johansson M, Borys F, Peterson H, et al. Addressing Harms Of Screening – A Review Of Outcomes In Cochrane Reviews And Suggestions For Next Steps. J Clin Epidemiol. 2021;129:68–73. https://linkinghub.elsevier.com/retrieve/pii/S0895435620311161
10. Nelson HD, Fu R, Cantor A, et al. Effectiveness Of Breast Cancer Screening: Systematic Review And Meta-Analysis To Update The 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016;164(4):244–55.